Paushak Ltd., a phosgene-based speciality chemicals and intermediates manufacturer based in India announced its results for the first quarter ended June 30, 2021.
Q1 Results- QoQ
The company’s net profit dropped 73.4% to Rs 2.93 crores ($0.4 million) for the period ended June 30, 2021 as against net profit of Rs 11.01 crores ($1.5 million) for the previous quarter.
Net sales declined 41% to Rs 23.57 crores ($3.2 million) during the period ended June 30, 2021 as compared to Rs 39.9 crores ($5.4 million) during the previous quarter.
Q1 Results- YoY
The company’s net profit declined 66.1% to Rs 2.93 crores ($0.4 million) for the period ended June 30, 2021 as against net loss of Rs 8.63 crores ($1.2 million) for the prior-year quarter.
Net sales decreased 30% to Rs 23.57 crores ($3.2 million) during the period ended June 30, 2021 as compared to Rs 33.59 crores ($4.5 million) during the prior-year quarter.
Shortage of oxygen during the second wave of COVID-19 has impacted the companies production output thereby affecting it sales revenue.
“During the quarter ended 30th June, 2021, due to resurgence of Covid-19 cases and prohibition on use of oxygen for industrial purposes, the Company had to temporarily suspend its manufacturing operations. While manufacturing was suspended for about 4-5 Weeks, the operations were adversely impacted for a much longer duration,” the company said in its stock exchange filings.
Paushak is engaged in the business of manufacture and selling of phosgene-based speciality chemicals and organic intermediates like isocyanates, chloroformates and carbonyl chlorides.